The Outcome of COVID-19 Infection in Patients With Gastrointestinal Diseases: An Experience at a Tertiary Center

Irgen Tafaj1, Liri Cuko1, Qazim Çili1

  • 1Gastroenterology and Hepatology, Mother Teresa University Hospital Center, Tirana, ALB.

Cureus
|April 3, 2023
PubMed

Insights

The coronavirus disease 2019 (COVID-19) pandemic significantly impacted hospitalized patients with digestive diseases, particularly those with liver cirrhosis. Inflammatory markers like neutrophil to lymphocyte ratio (NLR) predict severe COVID-19 outcomes.

Area of Science:

  • Gastroenterology
  • Hepatology
  • Infectious Diseases
  • Pulmonology

Background:

  • The COVID-19 pandemic presented unique challenges for patients with pre-existing digestive and liver conditions.
  • Understanding the interplay between COVID-19 infection and digestive diseases is crucial for effective patient management.

Purpose of the Study:

  • To investigate the impact of the COVID-19 pandemic on hospitalized patients with digestive diseases.
  • To analyze the relationship between COVID-19 severity and pre-existing conditions like liver cirrhosis.
  • To evaluate the utility of inflammatory markers in predicting COVID-19 outcomes in this patient group.

Main Methods:

  • Retrospective study of 41 COVID-19 positive patients (>18 years) admitted between June 2020 and December 2021.
  • COVID-19 severity assessed via hematological/biochemical parameters, oxygenation, and CT imaging.
  • Analysis of digestive disease prevalence, including cirrhosis, pancreatitis, and IBD.

Main Results:

  • Digestive diseases observed in 1.6% of hospitalized patients; cirrhosis was the most frequent (31.7%).
  • Elevated liver enzymes (AST, ALT) and bilirubin were common; higher creatinine, NLR, and MLR correlated with fatalities.
  • Cirrhosis patients experienced more severe COVID-19, requiring oxygen therapy (p<0.046), and a strong correlation existed between oxygen need and mortality (p<0.001).

Conclusions:

  • Comorbidities like liver cirrhosis significantly worsen COVID-19 severity and mortality.
  • Inflammatory indices, specifically NLR and MLR, are valuable predictors of severe disease progression in COVID-19 patients.
Abstract

Related Concept Videos

Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
352
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
164
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
379
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
408
Gastritis-I: Introduction and Types01:27

Gastritis-I: Introduction and Types

Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
632
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
128